HomeInsightsStock Comparison

Dr Reddys Laboratories Ltd vs Emcure Pharmaceuticals Ltd Stock Comparison

Dr Reddys Laboratories Ltd vs Emcure Pharmaceuticals Ltd Stock Comparison

Last Updated on: Jun 13, 2025

Key Highlights

  • The Latest Trading Price of Dr Reddys Laboratories Ltd is ₹ 1363 as of 12 Jun 15:30.
  • The P/E Ratio of Dr Reddys Laboratories Ltd changed from 25.6 on March 2020 to 18.4 on March 2024 . This represents a CAGR of -6.39% over 5 yearsThe P/E Ratio of Emcure Pharmaceuticals Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 51797 crore on March 2020 to ₹ 102679 crore on March 2024 . This represents a CAGR of 14.67% over 5 yearsThe Market Cap of Emcure Pharmaceuticals Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The revenue of Dr Reddys Laboratories Ltd for the Mar '25 is ₹ 9056 crore as compare to the Dec '24 revenue of ₹ 8535 crore. This represent the growth of 6.1% The revenue of Emcure Pharmaceuticals Ltd for the Mar '25 is ₹ 2120 crore as compare to the Dec '24 revenue of ₹ 1959 crore. This represent the growth of 8.23%.
  • The ebitda of Dr Reddys Laboratories Ltd for the Mar '25 is ₹ 2525 crore as compare to the Dec '24 ebitda of ₹ 2427 crore. This represent the growth of 4.04% The ebitda of Emcure Pharmaceuticals Ltd for the Mar '25 is ₹ 396.48 crore as compare to the Dec '24 ebitda of ₹ 358.5 crore. This represent the growth of 10.59%.
  • The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1405 crore to ₹ 1586 crore over 8 quarters. This represents a CAGR of 6.27% The net profit of Emcure Pharmaceuticals Ltd changed from ₹ 140.97 crore to ₹ 197.24 crore over 8 quarters. This represents a CAGR of 18.29% .
  • The Dividend Payout of Dr Reddys Laboratories Ltd changed from 14.14 % on March 2020 to 15.37 % on March 2024 . This represents a CAGR of 1.68% over 5 yearsThe Dividend Payout of Emcure Pharmaceuticals Ltd changed from 25.8 % on March 2020 to 22.53 % on March 2024 . This represents a CAGR of -2.67% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Dr Reddys Laboratories Ltd

  • Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Through its three businesses - Pharmaceutical Services &Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
  • The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
  • Dr. Reddy's operates in markets across the globe.
  • Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

About Emcure Pharmaceuticals Ltd

  • Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited', as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay.
  • Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited', through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001. Emcure Pharmaceuticals an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
  • They are a research and development driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which has enabled to reach target markets across over 70 countries, with a strong presence in India, Europe and Canada.

Dr Reddys Laboratories Ltd News Hub

News

Dr Reddys Laboratories Ltd up for third consecutive session

Dr Reddys Laboratories Ltd is up for a third straight session today. The stock is quoting ...

Read more

12 Jun 2025 13:05

News

Dr Reddys Laboratories Ltd soars 0.07%, up for fifth straight session

Dr Reddys Laboratories Ltd gained for a fifth straight session today. The stock is quoting...

Read more

09 Jun 2025 13:00

News

Alvotech and Dr Reddy's enter into collaboration and license agreement for pembrolizumab

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manu...

Read more

05 Jun 2025 09:20

News

Dr Reddys Lab gains on global biosimilar deal with Alvotech

Keytruda, a widely used immunotherapy for various cancer types, recorded global sales of $...

Read more

05 Jun 2025 10:10

News

Dr Reddys Laboratories allots 57,840 equity shares under ESOS

Dr Reddys Laboratories has allotted 57,840 equity shares of Re.1/- each of the Company, fu...

Read more

03 Jun 2025 16:28

News

Dr Reddys Labs' manufacturing facility gets two form 483 observations from US FDA

In a regulatory filing made on Saturday (24 May 2025), the company informed that the US FD...

Read more

26 May 2025 09:33

Emcure Pharmaceuticals Ltd News Hub

News

Board of Emcure Pharmaceuticals recommends final dividend

Emcure Pharmaceuticals announced that the Board of Directors of the Company at its meeting...

Read more

22 May 2025 18:02

News

Emcure Pharmaceuticals to announce Quarterly Result

Emcure Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 22 ...

Read more

14 May 2025 15:15

News

Emcure Pharma's pune facility receives VAI status from USFDA

The company received the Establishment Inspection Report (EIR) from the USFDA following an...

Read more

21 Apr 2025 11:09

News

Emcure subsidiary Tillomed Laboratories to acquire UK based Manx Healthcare and its subsidiaries

Tillomed Laboratories, a subsidiary of Emcure Pharmaceuticals, has entered into an Asset P...

Read more

04 Apr 2025 12:28

News

Emcure Pharma's European arm acquires Manx Healthcare for '19.7 million

The APA has also been inked with the subsidiaries of Manx, viz. Manx Pharma and Manx Gener...

Read more

04 Apr 2025 14:05

News

Emcutix Biopharmaceuticals inks in-licensing agreement with WiQo

Emcutix Biopharmaceuticals, a wholly owned subsidiary of Emcure Pharmaceuticals, announced...

Read more

02 Apr 2025 10:35

SWOT Analysis Of Dr Reddys Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Emcure Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Dr Reddys Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Dr Reddys Laboratories Ltd and Emcure Pharmaceuticals Ltd

Which company has a larger market capitalization, Dr Reddys Laboratories Ltd or Emcure Pharmaceuticals Ltd?

Market cap of Dr Reddys Laboratories Ltd is 113,756 Cr while Market cap of Emcure Pharmaceuticals Ltd is 26,112 Cr

What are the key factors driving the stock performance of Dr Reddys Laboratories Ltd and Emcure Pharmaceuticals Ltd?

The stock performance of Dr Reddys Laboratories Ltd and Emcure Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dr Reddys Laboratories Ltd and Emcure Pharmaceuticals Ltd?

As of June 13, 2025, the Dr Reddys Laboratories Ltd stock price is INR ₹1363.15. On the other hand, Emcure Pharmaceuticals Ltd stock price is INR ₹1378.1.

How do dividend payouts of Dr Reddys Laboratories Ltd and Emcure Pharmaceuticals Ltd compare?

To compare the dividend payouts of Dr Reddys Laboratories Ltd and Emcure Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions